← Every applicant
Cadila Pharms Ltd FDA Approvals
9 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| OLMESARTAN MEDOXOMILNew drugNov 8, 2024TABLET, ORAL |
| SILDENAFIL CITRATENew drugNov 28, 2023TABLET, ORAL |
| ATORVASTATIN CALCIUMNew drugOct 16, 2023TABLET, ORAL |
| PREGABALINNew drugJul 12, 2023CAPSULE, ORAL |
| OLANZAPINENew drugFeb 24, 2023TABLET, ORAL |
| ERYTHROMYCIN ETHYLSUCCINATENew drugNov 21, 2022GRANULE, ORAL |
| NEBIVOLOL HYDROCHLORIDENew drugDec 17, 2021TABLET, ORAL |
| PAROXETINE HYDROCHLORIDENew drugAug 27, 2021TABLET, EXTENDED RELEASE, ORAL |
| ERYTHROMYCINNew drugJun 28, 2021TABLET, ORAL |